Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FDMT vs CGON: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CGON Captures Overall Composite Edge (45.0 HOLD vs 51.3 HOLD), While FDMT Leads 3–2 on Growth & Valuation Pillars
CGON Overall Winner
6-Pillar Tally: FDMT 3 – 2 CGON (1 Tie)
Matrix Metrics: FDMT 3 – 5 CGON
As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (45.0/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.41 (N/M Forward P/E, -222.7% operating margin) versus CGON at $84.94 (N/M Forward P/E, -4293.5% operating margin).
- Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -222.7% operating margin) and revenue trajectory (-3.7% vs. +4505.6% YoY).
- Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FDMT vs CGON
FDMT
4D Molecular Therapeutics, Inc. Common Stock
$11.41
-6.7% 1D
Market Cap
$669.3M
TTM Revenue
$96M
Forward P/E
N/M
Beta / 30D Vol
1.90β · 91% Vol
Unified Composite Score
51.3
HOLD
Tech 51.0
Fund 47.0
Flow 66.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
CGON
Head-to-Head Winner
CG Oncology, Inc. Common stock
$84.94
+14.16% 1D
Market Cap
$6.3B
TTM Revenue
$6.2M
Forward P/E
N/M
Beta / 30D Vol
0.77β · 86% Vol
Unified Composite Score
45.0
HOLD
Tech 15.0
Fund 44.0
Flow 69.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (FDMT 3 – 2 CGON)
1. Valuation Multiples
FDMT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
6.6x
N/M
2. Growth & Scale
FDMT
Revenue Growth (YoY)
+4505.6%
-3.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$96M
$6.2M
Market Cap
$669.3M
$6.3B
3. Profitability & Quality
CGON
Gross Margin
N/A
N/A
Operating Margin
-222.7%
-4293.5%
Net Profit Margin
-208.6%
0.0%
Return on Equity (ROE)
-56.7%
-28.3%
4. Balance Sheet & Cash Flow
FDMT
Cash Generation (TTM)
-$156M
-$189M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$31M Net Cash
$19M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CGON
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
82.4% (10th %ile)
238.6% (85th %ile)
Put/Call OI Skew
5.16x (Put-Skewed)
0.35x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FDMT (3) vs CGON (5)| Institutional Metric | FDMT | CGON | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $669.3M | $6.3B | CGON | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +4505.6% | -3.7% | FDMT | |
| Operating Margin (TTM) | -222.7% | -4293.5% | FDMT | |
| Net Profit Margin | -208.6% | 0.0% | CGON | |
| Return on Equity (ROE) | -56.7% | -28.3% | CGON | |
| 52-Week Range Position | 45% ($7–$17) | 84% ($37–$94) | CGON | |
| Beta / 30D Volatility | 1.90β · 91% Vol | 0.77β · 86% Vol | CGON | |
| Unified Institutional Score | 51.3 / 100 (HOLD) | 45.0 / 100 (HOLD) | FDMT | |
| Trailing 12M Revenue (USD) | $96M | $6.2M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 6.6x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$156M ($31M Net Cash) | -$189M ($19M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CGON +47.92 pp
3M Horizon
CGON +33.82 pp
6M Horizon
FDMT +1.43 pp
1Y Horizon
CGON +113.94 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FDMT Revenue | CGON Revenue | FDMT Op. Margin | CGON Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -729.4% | N/A | FDMT |
| FY2020 | $10M | N/A | -424.0% | N/A | FDMT |
| FY2021 | $20M | N/A | -395.5% | N/A | FDMT |
| FY2022 | $0M | N/A | -3516.5% | N/A | FDMT |
| FY2023 | $20M | $0M | -544.6% | -27180.9% | FDMT |
| FY2024 | $0M | $0M | -507678.4% | -10067.3% | CGON |
| FY2025 | $90M | $0M | -187.2% | -4722.1% | FDMT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FDMT
BREAKDOWN
Current IV
82.4%
IV Percentile
10th %ile
Put/Call OI Skew
5.16x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CGON
CONSOLIDATION
Current IV
238.6%
IV Percentile
85th %ile
Put/Call OI Skew
0.35x (Call-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FDMT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CGON Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ FDMT vs CGON Key Questions & Quantitative Answers
As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (45.0/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.41 (N/M Forward P/E, -222.7% operating margin) versus CGON at $84.94 (N/M Forward P/E, -4293.5% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -222.7% operating margin) and revenue trajectory (-3.7% vs. +4505.6% YoY). Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with CGON at -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), FDMT cumulative revenue shifted +800.0% while CGON shifted N/A. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGON.
FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus CGON (-28.3% ROE) capital efficiency.
In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.90β · 91% Vol realized risk). By comparison, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CGON vs FDMT · Reverse Pair
FDMT vs STOK
· Sector Peer
FDMT vs ANNX
· Sector Peer
FDMT vs CGEM
· Sector Peer
CGON vs AVBP
· Sector Peer
CGON vs SYRE
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem